Ethris

Influenza virus
#Collaboration #Ethris #Lonza #mRNA #mRNA-based vaccines #Respiratory

Partners develop non-invasive mRNA vaccines

Ethris and Lonza have announced a collaboration to develop room-temperature stable, spray-dried formulations of mRNA-based vaccine candidates.  The vaccines are designed for mucosal delivery and offer a promising approach to combat respiratory diseases.  Room-temperature stability aims to address significant supply chain challenges associated with some… Read More

#News

Human heart
#Cardiovascular disease #Ethris #Heart attack #Heart failure #Heqet Therapeutics #Partnership #RNA

Partners hope to regenerate heart tissue using ncRNA

Ethris and Heqet Therapeutics have revealed plans to collaborate on RNA-based therapeutics for heart attack and heart failure, using non coding RNAs (ncRNAs) in regenerating heart tissue. Under the terms of the agreement, Heqet Therapeutics will lead the development of the programme, while Ethris will provide… Read More

#Business & Investment #News